IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Czechsinthemail who wrote (1207)	8/18/1997 9:48:00 AM
From: scaram(o)uche	of 1762

Yes, a strong competitor is coming from Coulter. However, see below. I'll try to join in any analysis. Perhaps GNE has some projections that are public or semi-public. However, I have a couple of questions to address, questions that really could sway our views..... first...... does anyone know if the bcl-2 story is being supported by further data. Is C2B8 plus CHOP therapy better for first-line therapy than CHOP alone? Second...... since C2B8 is chimeric and the Coulter product is murine, would successful CHOP plus C2B8 completely push Coulter out of the market. That is, if C2B8 and CHOP were to become standard first-line therapy, would the mouse epitopes shared between C2B8 and the Coulter product effectively prevent subsequent use of the radioconjugate? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next